Investigational New Drugs

, Volume 28, Issue 3, pp 343–349

Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer

  • Sung Yong Oh
  • Hyun Jin Kim
  • Tae Hyo Kim
  • Gyeong-Won Lee
  • Hoon Gu Kim
  • Chi-Young Jeong
  • Hyuk-Chan Kwon
  • Jung Hun Kang
PHASE II STUDIES

DOI: 10.1007/s10637-009-9265-1

Cite this article as:
Oh, S.Y., Kim, H.J., Kim, T.H. et al. Invest New Drugs (2010) 28: 343. doi:10.1007/s10637-009-9265-1

Summary

Background Gemcitabine- and 5-fluorouracil (5-FU)- based chemotherapy is a commonly used adjuvant or palliative treatment for patients with pancreatic cancer. However, a standard chemotherapy regimen has yet to be developed for patients refractory to gemcitabine and 5-FU treatment. We attempted to evaluate the efficacy and safety of a combination of irinotecan and oxaliplatin (IROX) as a salvage treatment for patients with gemcitabine- and 5-FU- refractory pancreatic cancer. Patients and Methods Patients with advanced pancreatic cancer who were refractory to prior gemcitabine- and 5-FU- based chemotherapy were enrolled in this study. IROX chemotherapy was administered as follows: Irinotecan, 150 mg/m2 on day 1; and oxaliplatin, 85 mg/m2 on day 1 over 90 min every 2 weeks. Result From Mar. 2006 to Dec. 2008, a total of 14 patients were administered 50 cycles of chemotherapy. The male-to-female ratio of the patient group was 11:3. These patients ranged in age from 48 to 73 years (median 65.5 years old). 3 patients (21.4%) evidenced partial responses. four patients (28.6%) exhibited stable disease. The median time to progression and overall survival time were 1.4 (95% CI: 1.2–1.6) months and 4.1 (95% CI: 2.0–6.2) months, respectively. Major hematologic toxicities included grade 1–2 anemia (88%), neutropenia (36%), thrombocytopenia (30%), and grade 3–4 neutropenia (10%). The most frequently detected non-hematological toxicities were grade 3 diarrheas (14%). Conclusion The IROX regimen appears to constitute a feasible and tolerable salvage therapy in patients with advanced pancreatic cancer who have been previously treated with gemcitabine- and 5-FU-based chemotherapy.

Keywords

IrinotecanOxaliplatinGemcitabine5-fluorouracilPancreatic cancer

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Sung Yong Oh
    • 1
  • Hyun Jin Kim
    • 2
    • 4
    • 5
  • Tae Hyo Kim
    • 2
    • 4
    • 5
  • Gyeong-Won Lee
    • 2
    • 4
    • 5
  • Hoon Gu Kim
    • 2
    • 4
    • 5
  • Chi-Young Jeong
    • 3
    • 4
    • 5
  • Hyuk-Chan Kwon
    • 1
  • Jung Hun Kang
    • 2
    • 4
    • 5
    • 6
  1. 1.Department of Internal MedicineDong-A University College of MedicineBusanKorea
  2. 2.Department of Internal MedicineGyeongsang National University School of MedicineJinjuKorea
  3. 3.Department of SurgeryGyeongsang National University School of MedicineJinjuKorea
  4. 4.Gyeongnam Regional Cancer CenterJinjuKorea
  5. 5.Gyeongsang Institute of Health ScienceJinjuKorea
  6. 6.Division of Hematology-Oncology, Department of Internal Medicine, College of MedicineGyeong-Sang National UniversityJinjuKorea